Galapagos Gets the BD ball rolling with option on Adaptimmune's uza-cel in HNSCC
Galapagos and Adaptimmune have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's uza-cel (TCR-T cell therapy targeting MAGE-A4) for head & neck cancer and potential future solid tumour indications, using Galapagos' decentralised cell manufacturing platform for an $ 70m upfront, $ 30m in R&D funding, as well as an option exercise fee of $ 100m, plus $ 465m in milestones, and tiered mid-single to low-double digit royalties. We welcome this deal which in our view gets the BD ball rolling, and leverages Galapagos' decentralised platform in the larg...